Stocks · News reference
8-K filing — Aura Biosciences, Inc. (AURA)
Filed: 2026-08-11 AccNo: 0001193125-26-343408 Size: 10 MB Item 2.02: Results of Operations and Financial Condition Item 2.05: Cost Associated with Exit or Disposal Activities Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Aura Biosciences May Offer Securities Up To $500M Aggregate; May Sell Up To $200M Common Stock Under Sales Agreement With Jefferies
- Sec Filing
HC Wainwright & Co. Maintains Buy on Aura Biosciences, Lowers Price Target to $18
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Aura Biosciences (NASDAQ:AURA) with a Buy and lowers the price target from $24 to $18.
Aura Biosciences Q2 EPS $(0.48) Misses $(0.38) Estimate
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.38) by 29.73 percent. This is a 2.13 percent decrease over losses of $(0.47) per share